Compounds > mitragynine
Page last updated: 2024-12-10

mitragynine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

speciogynine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3034396
CHEMBL ID299031
CHEBI ID6956
SCHEMBL ID875799
SCHEMBL ID875800
MeSH IDM0042144
PubMed CID15560577
CHEMBL ID4859858
SCHEMBL ID15979410
MeSH IDM0042144

Synonyms (45)

Synonym
4098-40-2
mitragynine
C09226
chebi:6956 ,
CHEMBL299031 ,
sk&f 12711
9-methoxycorynantheidine
ep479k822j ,
skf 12711
hsdb 7901
(-)-mitragynine
unii-ep479k822j
16,17-didehydro-9,17-dimethoxy-17,18-seco-20-alpha-yohimban-16-carboxylic acid methyl ester
mitragynin
(.alpha.e,2s,3s,12.beta.s)-3-ethyl-1,2,3,4,6,7,12,12b-octahydro-8-methoxy-.alpha.-(methoxymethylene)-indolo(2,3-a)quinolizine-2-acetic acid methyl ester
mitragynine [mi]
mitragynine [who-dd]
indolo(2,3-a)quinolizine-2-acetic acid, 3-ethyl-1,2,3,4,6,7,12,12b-octahydro-8-methoxy-.alpha.-(methoxymethylene)-, methyl ester, (.alpha.e,2s,3s,12bs)-
SCHEMBL875799
SCHEMBL875800
methyl (2e)-2-[(2s,4s,5s)-5-ethyl-12-methoxy-7,17-diazatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),11,13,15-tetraen-4-yl]-3-methoxyprop-2-enoate
bdbm50474152
Q414299
methyl(e)-2-[(2s,3s,12bs)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
mitragynine picrate
mitragynine - 95%
BM164595
DTXSID701032140
mitragynine 100 microg/ml in methanol
mitragynine, 1mg/ml in methanol
mitragynine, 0.1mg/ml in methanol
4697-67-0
speciogynine
SCHEMBL15979410
17,18-secoyohimban-16-carboxylic acid, 16,17-didehydro-9,17-dimethoxy-, methyl ester, (e)-
indolo(2,3-a)quinolizine-2-acetic acid, 3-ethyl-1,2,3,4,6,7,12,12b-octahydro-8-methoxy-alpha-(methoxymethylene)-, methyl ester, (alphae,2s,3r,12bs)-
unii-bb185of16a
indolo(2,3-a)quinolizine-2-acetic acid, 3-ethyl-1,2,3,4,6,7,12,12b-octahydro-8-methoxy-.alpha.-(methoxymethylene)-, methyl ester, (.alpha.e,2s,3r,12bs)-
(+)-speciogynine
BB185OF16A ,
(16e)-16,17-didehydro-9,17-dimethoxycorynan-16-carboxylic acid methyl ester
DTXSID901318037
methyl (e)-2-[(2s,3r,12bs)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
CHEMBL4859858 ,
bdbm50566316

Research Excerpts

Overview

Mitragynine (MG) is a major alkaloidal component in the Thai traditional medicinal herb, Mitragyna speciosa. It has been proven to exhibit analgesic activity mediated by opioid receptors.

ExcerptReferenceRelevance
"Mitragynine (1) is a major alkaloidal component in the Thai traditional medicinal herb, Mitragyna speciosa, and has been proven to exhibit analgesic activity mediated by opioid receptors. "( Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
Aimi, N; Horie, S; Ishikawa, H; Kitajima, M; Koyama, F; Kurihara, M; Matsumoto, K; Moriyama, T; Murayama, T; Ponglux, D; Takayama, H; Watanabe, K; Yamamoto, LT, 2002)		2
"Mitragynine (MG) is a pharmacologically active alkaloid derived from the leaves of Mitragyna speciosa Korth (Kratom). "( Mitragynine, a primary constituent of kratom reinstates morphine-seeking behaviour in rats.
Harun, N; Hassan, Z; Japarin, RA; Shoaib, M, 2023)		3.8
"Mitragynine (MG) is an alkaloid found in Mitragyna speciosa (kratom), a plant used to self-treat symptoms of opioid withdrawal and pain. "( Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain.
Bradshaw, HB; Farkas, DJ; Heydari, LN; Inan, S; Johnson, CT; Rawls, SM; Ward, SJ; Zhao, P, 2023)		2.58
"Mitragynine (MG) is an indole alkaloid found in the extract of Mitragyna speciosa Korth native to Southeast Asia. "( Effects of mitragynine on viability, proliferation, and migration of C6 rat glioma, SH-SY5Y human neuroblastoma, and HT22 immortalized mouse hippocampal neuron cell lines.
Mukda, S; Viwatpinyo, K; Warinhomhoun, S, 2023)		2.74
"Mitragynine is a major psychoactive alkaloid in leaves of kratom ("( Development of a Physiologically Based Pharmacokinetic Model of Mitragynine, Psychoactive Alkaloid in Kratom (
Lohitnavy, M; Methaneethorn, J; Trakulsrichai, S; Tran, QB; Wananukul, W; Ya, K, )		1.81
"Mitragynine is a novel psychoactive substance (NPS) that has emerged as a designer opioid being distributed on the street. "( Suspected Driving Under the Influence Case Involving Mitragynine.
Wright, TH, 2018)		2.17
"Mitragynine is a major component isolated from Mitragyna speciosa Korth or kratom, a medicinal plant known for its opiate-like and euphoric properties. "( The inhibitory effects of mitragynine on P-glycoprotein in vitro.
Adenan, MI; Amanah, A; Kaur, G; Rusli, N; Sulaiman, SF; Tan, ML; Wahab, HA, 2019)		2.26
"Mitragynine is a major bioactive compound of Kratom, which is derived from the leave extracts of Mitragyna speciosa Korth or Mitragyna speciosa (M. "( Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.
Adenan, MI; Jamil, MF; Lu, J; Shim, W; Tan, ML; Wei, H; Wong, P; Wu, J, 2014)		2.12
"Mitragynine is a lipophilic alkaloid, as indicated by a logP value of 1.73."( Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation.
Magosso, E; Mansor, SM; Murugaiyah, V; Parthasarathy, S; Ramanathan, S; Tan, SC, 2015)		1.39
"Mitragynine is a major indole alkaloid isolated from the Thai medicinal plant Mitragyna speciosa that has opium-like properties, although its chemical structure is quite different from that of morphine. "( MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with pot
Horie, S; Kitajima, M; Matsumoto, K; Misawa, K; Murayama, T; Nakamura, A; Narita, M; Suzuki, M; Suzuki, T; Takayama, H; Tashima, K; Wongseripipatana, S, 2008)		1.98
"Mitragynine (MG) is an indole alkaloid of the Thai medicinal plant Mitragyna speciosa (Kratom in Thai) and reported to have opioid agonistic properties. "( Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry.
Kanogsunthornrat, J; Klein, ON; Maurer, HH; Philipp, AA; Wissenbach, DK; Zoerntlein, SW, 2009)		2.09
"Mitragynine is a pharmacologically-active terpenoid indole alkaloid found in Mitragyna speciosa leaves. "( Methyl jasmonate and yeast extract stimulate mitragynine production in Mitragyna speciosa (Roxb.) Korth. shoot culture.
Charoonratana, T; Choo-Malee, J; Keawpradub, N; Wungsintaweekul, J, 2012)		2.08
"Mitragynine is an indole alkaloid isolated from the Thai medicinal plant Mitragyna speciosa. "( Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa.
Aimi, N; Horie, S; Ishikawa, H; Matsumoto, K; Ponglux, D; Takayama, H; Watanabe, K, 2004)		2.04
"Mitragynine is an indole alkaloid isolated from the Thai medicinal plant Mitragyna speciosa that is reported to have opioid agonistic properties. "( Partial agonistic effect of 9-hydroxycorynantheidine on mu-opioid receptor in the guinea-pig ileum.
Aimi, N; Horie, S; Ishikawa, H; Matsumoto, K; Ponglux, D; Takayama, H; Watanabe, K, 2006)		1.78
"Mitragynine is a major alkaloidal constituent extracted from the young leaves of Mitragyna speciosa Korth. "( Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors.
Aimi, N; Matsumoto, K; Mizowaki, M; Sakai, S; Suchitra, T; Takayama, H; Watanabe, H, 1996)		2.04
"Mitragynine is a major alkaloidal constituent of young leaves of Mitragyna speciosa Korth, that is known to exhibit narcotic-like activity. "( Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems.
Aimi, N; Matsumoto, K; Mizowaki, M; Murakami, Y; Sakai, S; Suchitra, T; Takayama, H; Watanabe, H, 1996)		2.01

Toxicity

ExcerptReferenceRelevance
" However, there have also been increasing numbers of reports of adverse effects resulting from use of kratom products."( Kratom policy: The challenge of balancing therapeutic potential with public safety.
Avery, BA; Boyer, EW; Grundmann, O; Henningfield, JE; Kruegel, AC; McCurdy, CR; McMahon, LR; Prozialeck, WC; Singh, D; Swogger, MT; Veltri, CA, 2019)		0.51

Pharmacokinetics

The method was successfully applied in pharmacokinetic and stability studies of mitragynine.

ExcerptReferenceRelevance
" This method was successfully applied to determine the pharmacokinetic characteristics of mitragynine levels in the serum of rats after it was administered orally."( A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats.
Chittrakarn, S; Janchawee, B; Keawpradub, N; Prasettho, S; Sawangjareon, K; Wararatananurak, P, 2007)		0.79
" The method was successfully applied in pharmacokinetic and stability studies of mitragynine."( Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat.
Adenan, MI; Ismail, S; Mansor, SM; Murugaiyah, V; Parthasarathy, S; Ramanathan, S, 2010)		0.93
" From data of nine subjects, the pharmacokinetic parameters established were time to reach the maximum plasma concentration (0."( Pharmacokinetics of mitragynine in man.
Auparakkitanon, S; Krongvorakul, J; Noumjad, N; Sathirakul, K; Sueajai, J; Sukasem, C; Trakulsrichai, S; Wananukul, W, 2015)		0.74
"This was the first pharmacokinetic study in humans, which demonstrated linearity and was consistent with the oral two-compartment model with a terminal half-life of about 1 day."( Pharmacokinetics of mitragynine in man.
Auparakkitanon, S; Krongvorakul, J; Noumjad, N; Sathirakul, K; Sueajai, J; Sukasem, C; Trakulsrichai, S; Wananukul, W, 2015)		0.74
" We have reviewed the published analgesic and pharmacokinetic studies and all of these findings showed the routes of drug administration, doses employed, and type of vehicles used to solubilize the drug, varied considerably; hence this posted difficulties in predicting the drug's pharmacokinetic-response relationship."( Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: present knowledge and future directions in perspective of pain.
Damodaran, T; Murugaiyah, V; Ramachandram, DS; Ramanathan, S; Zainal, H, 2019)		0.78

Bioavailability

ExcerptReferenceRelevance
"The obtained ADME and cytotoxicity data demonstrated that both MSAE and mitragynine have poor bioavailability and have the potential to be significantly cytotoxic."( Physicochemical Characterization of Mitragyna speciosa Alkaloid Extract and Mitragynine using In Vitro High Throughput Assays.
Alshawsh, MA; Chik, Z; Kong, WM; Mohamed, Z, 2017)		0.92
"2 L/hr/kg), and absolute oral bioavailability (20."( Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method.
Avery, BA; Berthold, EC; Kamble, SH; King, TI; León, F; McCurdy, CR; McMahon, LR; Popa, R; Raju, KS; Sharma, A, 2021)		0.62

Dosage Studied

ExcerptRelevanceReference
" The understanding of mitragynine derivative metabolism in human body is required to develop effective detection techniques in case of drug abuse or establish an appropriate dosage in case of medicinal uses."( In silico investigation of mitragynine and 7-hydroxymitragynine metabolism.
Limpanuparb, T; Noorat, R; Tantirungrotechai, Y, 2019)		1.13
" A rational approach is warranted for accurate prediction of dose-response relationship; as this is essential for the development of MG as an alternative medicinal drug for pain management."( Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: present knowledge and future directions in perspective of pain.
Damodaran, T; Murugaiyah, V; Ramachandram, DS; Ramanathan, S; Zainal, H, 2019)		0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoid indole alkaloidA terpenoid indole alkaloid which is biosynthesised from L-tryptophan and diisoprenoid (usually secolaganin) building blocks.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki5.88000.00010.532610.0000AID1830045
Alpha-2A adrenergic receptorHomo sapiens (human)Ki4.72000.00010.807410.0000AID1581731
Cytochrome P450 2D6Homo sapiens (human)Ki1.10000.00011.19868.0000AID1775306
Alpha-2B adrenergic receptorHomo sapiens (human)Ki9.29000.00020.725710.0000AID1581732
Alpha-2C adrenergic receptorHomo sapiens (human)Ki2.32000.00030.483410.0000AID1581733
Alpha-1D adrenergic receptorHomo sapiens (human)Ki5.48000.00000.360910.0000AID1581730
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki5.01000.00000.385510.0000AID1830041
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki10.00000.00010.954910.0000AID1830039
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)4.00000.00010.729810.0000AID1629752
Delta-type opioid receptorMus musculus (house mouse)Ki1.01100.00000.53939.4000AID1629755
Kappa-type opioid receptorMus musculus (house mouse)IC50 (µMol)4.00000.00131.538010.0000AID1629759
Kappa-type opioid receptorMus musculus (house mouse)Ki0.23100.00030.35942.7500AID1629754
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki10.00000.00030.380610.0000AID1830042
Alpha-1A adrenergic receptorHomo sapiens (human)Ki1.34000.00000.272610.0000AID1581728
Alpha-1B adrenergic receptorHomo sapiens (human)Ki4.77000.00000.471310.0000AID1581729
Mu-type opioid receptorHomo sapiens (human)Ki0.18500.00000.419710.0000AID1581727; AID1749821; AID1872031
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)10.00000.00020.75218.0140AID1872150
Delta-type opioid receptorHomo sapiens (human)Ki10.00000.00000.59789.9300AID1872032
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki1.00000.00000.20186.4240AID754487
Kappa-type opioid receptorHomo sapiens (human)Ki0.48500.00000.362410.0000AID1581726; AID1872033
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki1.26000.00030.769310.0000AID1830040
Mu-type opioid receptorMus musculus (house mouse)Ki0.23000.00000.12281.3000AID1629753
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00720.00000.27869.0000AID754489
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.06700.00010.532610.0000AID1830044; AID1830045
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki1.32000.00000.385510.0000AID1830041
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki5.43000.00010.954910.0000AID1830039
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki1.60000.00030.380610.0000AID1830042
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)5.70000.00010.813310.0000AID1872149
Mu-type opioid receptorHomo sapiens (human)Ki0.72800.00000.419710.0000AID1749821; AID1872031
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)10.00000.00020.75218.0140AID1872150
Delta-type opioid receptorHomo sapiens (human)Ki10.00000.00000.59789.9300AID1872032
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)10.00000.00001.201110.0000AID1872151
Kappa-type opioid receptorHomo sapiens (human)Ki3.20000.00000.362410.0000AID1872033
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.06550.00030.769310.0000AID1830038; AID1830040
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)0.24540.00000.32639.4000AID1581734; AID1581748; AID1809484; AID1872142
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)8.50000.00000.22448.9900AID1872153
Mu-type opioid receptorMus musculus (house mouse)EC50 (µMol)0.20300.00020.03930.2030AID1629756
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Kb0.17920.00000.03310.1792AID1581737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (209)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneKappa-type opioid receptorMus musculus (house mouse)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (297)

Assay IDTitleYearJournalArticle
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1775301Dose normalized Cmax in Sprague-Dawley rat plasma at 9.6 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1872033Binding affinity to KOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID222755activity evaluated by its ability to inhibit the electrically induced twitch contraction in guinea pig ileum, which is reversed by naloxone (300 nM)(P < 0.01)2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1581712Displacement of [3H]DADLE from human recombinant delta opioid receptor expressed in rat Chem-1 (RBL) cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID754489Displacement of [3H]DAMGO from mu opoid receptor in Dunkin-Hartley guinea pig brain after 1.5 hrs by liquid scintillation spectrometry2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID1775306Inhibition of CYP2D6 in human liver microsomes assessed as inhibition of dextromethorphan O-demethylation using dextromethorphan as substrate preincubated for 5 mins followed by NADPH addition by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830048Displacement of [125I](+/-)DOI from human recombinant 5-HT2C receptor expressed in CHO cells at 10 uM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1872142Agonist activity at MOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1581742Competitive antagonist activity at human recombinant adrenergic alpha-1B receptor expressed in CHO cells assessed as inhibition of epinephrine-induced intracellular calcium levels incubated at room temperature by fluorimetry2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775282Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured at -80 degC for 4 weeks by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775322Drug metabolism in Sprague-Dawley rat plasma assessed as 7-HMG metabolite formation by measuring percentage metabolic ratio of AUC(0-24 hrs) of 7-HMG/AUC(0-24hrs) of parent compound at 5.73 mg/kg, po administered as LKT formulation measured for 24 hrs by 2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830035Displacement of [125I]CYP from rat cerebral cortex 5-HT1B receptor at 100 nM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830045Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in CHO cells measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1629753Displacement of [125I]-IBNtxA from mouse mu opioid receptor-1 expressed in CHO cell membranes incubated for 90 mins2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID148204Binding affinity using guinea pig brain membrane preparations, towards Opioid receptor mu 1 using [3H]- DAMGO as radioligand2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1581727Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID754479Inhibition of gastrointestinal transit of charcoal meal in rat at 55.2 mg/kg, po2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID1830062Antinociceptive activity against Sprague-Dawley rats assessed as lower lip retraction at 56 mg/kg, ip measured for 15 mins2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581748Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of cAMP accumulation by HTRF assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581708Displacement of [3H]prazosin from human recombinant adrenergic alpha-1B receptor expressed in CHO cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1872155Antinociceptive activity in po dosed mouse by tail flick assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1581741Competitive antagonist activity at human recombinant adrenergic alpha-1A receptor expressed in CHO cells assessed as inhibition of epinephrine-induced intracellular calcium levels incubated at room temperature by fluorimetry2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1629759Antagonist activity at mouse kappa opioid receptor-1 expressed in CHO cell membranes assessed as inhibition of U50,488H-induced [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1581715Displacement of radioligand from ORL1 (unknown origin) at 100 nM incubated for 120 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID150056Binding affinity using guinea pig brain membrane preparations, towards Opioid receptor delta 1 using [3H]DPDPE as radioligand2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1830047Displacement of [3H]BRL43694 from human recombinant 5-HT3 receptor expressed in CHO cells at 100 nM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1610010Inhibition of kappa opioid receptor in guinea pig brain membranes2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1629757Agonist activity at mouse mu opioid receptor-1 expressed in CHO cell membranes assessed as [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis relative to DAMGO2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1581750Metabolic stability in human liver microsomes assessed as elimination rate constant in presence of NADPH incubated up to 60 mins by UPLC-MS/MS analysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775337Dose normalized Cmax in rat plasma at 20 mg/kg, po administered as LKT formulation2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581729Displacement of [3H]prazosin from human recombinant adrenergic alpha-1B receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID222419Relative inhibitory activity expressed as the percentage of the maximum inhibition by the compound against that of morphine2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1830039Displacement of [3H]LSD from human recombinant 5-HT2C receptor expressed in HEK cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581752Fraction unbound in human plasma at 1 uM by equilibrium dialysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID754485Selectivity ratio of Ki for mu opioid receptor in Dunkin-Hartley guinea pig brain over Ki for kappa opioid receptor in Dunkin-Hartley guinea pig brain2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID1610009Inhibition of delta opioid receptor in guinea pig brain membranes2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1581725Displacement of [3H]DADLE from human recombinant delta opioid receptor expressed in rat Chem-1 (RBL) cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1629755Displacement of [125I]-IBNtxA from mouse delta opioid receptor-1 expressed in CHO cell membranes incubated for 90 mins2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1775342Stability of the compound in water-methanol mixture (1:1) assessed as drug recovery2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581734Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of cAMP accumulation incubated for 10 mins by HTRF assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775305Dose normalized AUC(0 to 24 hrs) in Sprague-Dawley rat plasma at 5.73 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581737Antagonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced of cAMP accumulation incubated for 10 mins by HTRF assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1610016Agonist activity at delta opioid receptor in guinea pig brain membranes by [35S]-GTPgammaS binding assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1775287Cmax in Sprague-Dawley rat plasma at 9.6 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1610017Agonist activity at kappa opioid receptor in guinea pig brain membranes by [35S]-GTPgammaS binding assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1830023AUCinfinity in Sprague-Dawley rat at 5 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID149837Relative affinity evaluated for Opioid receptor kappa 12002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1581740Partial agonist activity at human recombinant adrenergic alpha-1D receptor expressed in rat RBL cells assessed as stimulation of intracellular calcium levels incubated at room temperature by fluorimetry2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1830051Displacement of [125I](+/-)DOI from human recombinant 5-HT2B receptor expressed in CHO cells at 100 nM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581721Displacement of [3H]DADLE from human recombinant delta opioid receptor expressed in rat Chem-1 (RBL) cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1809484Agonist activity at human MOR expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.
AID1581743Competitive antagonist activity at human recombinant adrenergic alpha-1D receptor expressed in rat RBL cells assessed as inhibition of epinephrine-induced intracellular calcium levels incubated at room temperature by fluorimetry2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581724Displacement of radioligand from ORL1 (unknown origin) at 10000 nM incubated for 120 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775288AUC(0 to 24 hrs) in Sprague-Dawley rat plasma at 9.6 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID754488Displacement of [3H]DPDPE from delta opoid receptor in Dunkin-Hartley guinea pig brain after 2 hrs by liquid scintillation spectrometry2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID222285% maximum inhibition is elicited when the response reaches plateau, calculated regarding electrically induced contraction in guinea pig ileum as 100%2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1581755Metabolic stability in human liver microsomes assessed as hepatic clearance in presence of NADPH incubated up to 60 mins by UPLC-MS/MS analysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1809486Agonist activity at human MOR receptor expressed in HTLA cells co-expressing TEV-fused-beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by Tango assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.
AID1581716Displacement of [3H]prazosin from human recombinant adrenergic alpha-1A receptor expressed in CHO cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1872150Inhibition of DOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1610015Agonist activity at mu opioid receptor in guinea pig brain membranes by [35S]-GTPgammaS binding assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID754476Agonist activity at opioid receptor in guinea pig ileum assessed as inhibition of electrically-induced twitch at 100 pM to 30 uM relative to morphine2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID1581720Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2B receptor expressed in CHO cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581756Metabolic stability in human liver microsomes assessed as hepatic extraction ratio in presence of NADPH incubated up to 60 mins by UPLC-MS/MS analysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581726Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775300Dose normalized AUC(0 to 24 hrs) in Sprague-Dawley rat plasma at 9.6 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581717Displacement of [3H]prazosin from human recombinant adrenergic alpha-1B receptor expressed in CHO cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1830041Displacement of [3H]LSD from human recombinant 5-HT2A receptor expressed in HEK cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775277Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured on the bench-top for 2 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830053Displacement of [125I](+/-)DOI from human recombinant 5-HT2A receptor expressed in HEK293 cells at 100 nM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581732Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2B receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1830032Displacement of [125I]CYP from rat cerebral cortex 5-HT1B receptor at 10 uM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581739Partial agonist activity at human recombinant adrenergic alpha-1A receptor expressed in CHO cells assessed as stimulation of intracellular calcium levels incubated at room temperature by fluorimetry2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581754Metabolic stability in human liver microsomes assessed as intrinsic clearance in presence of NADPH incubated up to 60 mins by UPLC-MS/MS analysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775280Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured under freeze-thaw conditions for 3 cycles by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775338Dose normalized AUC in rat plasma at 20 mg/kg, po administered as LKT formulation2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775324Drug metabolism in Beagle dog plasma assessed as percentage metabolic ratio at 5 mg/kg, po2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1872152Agonist activity at MOP (unknown origin) relative to control2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1749821Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis
AID1872032Binding affinity to DOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID754486Selectivity ratio of Ki for mu opioid receptor in Dunkin-Hartley guinea pig brain over Ki for delta opioid receptor in Dunkin-Hartley guinea pig brain2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID1610019Agonist activity at delta opioid receptor in guinea pig brain membranes by [35S]-GTPgammaS binding assay relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1581751Metabolic stability in human liver microsomes assessed as half life in presence of NADPH incubated up to 60 mins by UPLC-MS/MS analysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581709Displacement of [3H]prazosin from human recombinant adrenergic alpha-1D receptor expressed in CHO cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581711Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2B receptor expressed in CHO cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1830040Displacement of [3H]LSD from human recombinant 5-HT2B receptor expressed in HEK cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775304Dose normalized Cmax in Sprague-Dawley rat plasma at 5.73 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID222586Relative potency expressed as the percentage of the pD2 value against that of morphine2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1830024Clearence in Sprague-Dawley rat at 5 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1629767Antinociceptive activity in sc dosed CD-1 mouse assessed as increase in reaction time measured 15 mins post dose by radiant heat tail flick assay2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1809485Agonist activity at human MOR expressed in HEK-293T cells assessed as inhibition of forskolin-stimulated cAMP accumulation incubated for 30 mins by Glo-sensor cAMP assay relative to DAMGO2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.
AID148190Relative affinity evaluated for Opioid receptor mu 12002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1830033Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in cells at 100 nM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830046Displacement of [3H]BRL43694 from human recombinant 5-HT3 receptor expressed in CHO cells at 10 uM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775279Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured in autosampler for 24 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581713Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775299Ratio of Dose normalized AUC(0 to 24 hrs) in Sprague-Dawley rat plasma at 9.6 mg/kg, po administered as OPMS liquid formulation to Dose normalized AUC(0 to 24 hrs) in Sprague-Dawley rat plasma at 5.73 mg/kg, po administered as LKT formulation2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581710Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2A receptor expressed in CHO cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775276AUC(0 to 24 hrs) in Sprague-Dawley rat plasma at 5.73 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581723Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581728Displacement of [3H]prazosin from human recombinant adrenergic alpha-1A receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1629756Agonist activity at mouse mu opioid receptor-1 expressed in CHO cell membranes assessed as [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1610018Agonist activity at mu opioid receptor in guinea pig brain membranes by [35S]-GTPgammaS binding assay relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1581753Fraction unbound in human liver microsomes at 1 uM by equilibrium dialysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1872153Agonist activity at KOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1775275Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured on the bench-top for 2 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775286Tmax in Sprague-Dawley rat plasma at 9.6 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830042Displacement of [3H]5-CT from human recombinant 5-HT7A receptor expressed in HEK cells by radioligand completion assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID149845Binding affinity using guinea pig brain membrane preparations, towards Opioid receptor kappa 1 using [3H]- U-69,593 as radioligand2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1775303Cmax in Sprague-Dawley rat plasma at 5.73 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775283Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured at -80 degC for 4 weeks by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830034Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in cells at 10 uM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581718Displacement of [3H]prazosin from human recombinant adrenergic alpha-1D receptor expressed in CHO cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775281Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured under freeze-thaw conditions for 3 cycles by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581722Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes at 1000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581719Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2A receptor expressed in CHO cell membranes at 10000 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775323Drug metabolism in Sprague-Dawley rat plasma assessed as 7-HMG metabolite formation by measuring percentage metabolic ratio of AUC(0-24 hrs) of 7-HMG/AUC(0-24hrs) of parent compound at 9.6 mg/kg, po administered as OPMS liquid formulation measured for 24 2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1809487Agonist activity at human MOR receptor expressed in HTLA cells co-expressing TEV-fused-beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by Tango assay relative to DAMGO2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.
AID1581731Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2A receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1775302Tmax in Sprague-Dawley rat plasma at 5.73 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1610020Agonist activity at kappa opioid receptor in guinea pig brain membranes by [35S]-GTPgammaS binding assay relative to control2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1775341Stability of the compound in rat plasma assessed as drug recovery2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1581733Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581707Displacement of [3H]prazosin from human recombinant adrenergic alpha-1A receptor expressed in CHO cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581749Toxicity in Sprague-Dawley rat assessed as induction of hypothermia at 0.0032 to 10 mg/kg, iv2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1872031Binding affinity to MOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID754487Displacement of [3H]U-69593 from kappa opoid receptor in Dunkin-Hartley guinea pig brain after 1 hr by liquid scintillation spectrometry2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID1581714Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes at 100 nM incubated for 60 mins relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1830059Antinociceptive activity against Sprague-Dawley rats assessed as lower lip retraction at 56 mg/kg, ip measured for 15 mins in presence of WAY1006352021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830052Displacement of [125I](+/-)DOI from human recombinant 5-HT2A receptor expressed in HEK293 cells at 10 uM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830050Displacement of [125I](+/-)DOI from human recombinant 5-HT2B receptor expressed in CHO cells at 10 uM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830021Elimination rate constant in Sprague-Dawley rat at 5 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1581730Displacement of [3H]prazosin from human recombinant adrenergic alpha-1D receptor expressed in CHO cell membranes incubated for 60 mins2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1629765Activation of mu opioid receptor-1 (unknown origin) expressed in CHO cells assessed as beta-arrestin-2 recruitment at 10 uM after 90 mins by beta-galactosidase complementation assay2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1581747Antinociceptive activity in Sprague-Dawley rat dosed intravenously using cumulative dosing every 5 mins until rat maxed-out on hot plate co-treated with 0.1 mg/kg naltrexone by hot plate test2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1629754Displacement of [125I]-IBNtxA from mouse kappa opioid receptor-1 expressed in CHO cell membranes incubated for 90 mins2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1830022Apparent volume of distributed in Sprague-Dawley rat at 5 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830037Antinociceptive activity against ip dosed Sprague-Dawley rats assessed as loser lip retraction measured for 15 mins2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1629752Antagonist activity at mouse delta opioid receptor-1 expressed in CHO cell membranes assessed as inhibition of DPDPE-induced [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
AID1581746Antinociceptive activity in Sprague-Dawley rat dosed intravenously using cumulative dosing every 5 mins until rat maxed-out on hot plate by hot plate test relative to control2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1581744Competitive antagonist activity at human recombinant adrenergic alpha-2C receptor expressed in CHO cells assessed as inhibition of epinephrine-induced intracellular calcium levels incubated at room temperature by fluorimetry2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID754481Antinociceptive activity in mouse at 92 mg/kg, po by hot plate test2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Orally active opioid compounds from a non-poppy source.
AID150051Relative affinity evaluated for Opioid receptor delta 12002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.
AID1775278Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured in autosampler for 24 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830049Displacement of [125I](+/-)DOI from human recombinant 5-HT2C receptor expressed in CHO cells at 100 nM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1610008Inhibition of mu opioid receptor in guinea pig brain membranes2019European journal of medicinal chemistry, Dec-01, Volume: 183Progress in the development of more effective and safer analgesics for pain management.
AID1872164Antinociceptive activity in sc dosed mouse2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1347353A2780 Cisplatin Sensitive Ovarian Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347363Firefly luciferase counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347352COV-362 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347345OV-KATE Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347348OV-SAHO Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347361HEK293 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347364KB-8-5-11 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347366KB-3-1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347392qHTS for activators of dead-cell proteases activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347370qHTS for ATAD5 Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347347UWB1.289 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347400Viability qHTS for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347355HEK-293 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347369MCF7 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347378qHTS for H2AX Agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347358HPAF-II 12hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347356HPAF-II 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347393qHTS for inhibitors of ER calcium dysfunction: SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347360HPAF-II 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347388qHTS for Activators of p53 Stress Response Pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347394Vero-766 cells viability qHTS against the NCATS CANVASS Library: Counterscreen for Zika virus inhibition assay2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347365SDT Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347367qHTS for ATAD5 Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347396qHTS for inhibitors of Wild type Zika virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347401Redox Reaction Profiling qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347377DH5-alpha competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347390Secretion counterscreen for inhibitors of the SERCaMP assay screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347357HEK293 18hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347349Panc-1005 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347375qHTS for Hypoxia signaling pathway (HIF-1) agonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347372qHTS for Constitutive Androstane Receptor (CAR) Antagonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347346HPAF-II Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347379qHTS for Inflammasome Signaling Inhibitors: IL-1-beta AlphaLISA screen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID134737610-beta competent E. coli microbial cell viability qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347391qHTS for activators of Nrf2/ARE signaling pathway screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347373qHTS for Constitutive Androstane Receptor (CAR) Agonist screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347350SW1088 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347387Cytotoxicity qHTS for assessment of Hepg2 cells membrane integrity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347374qHTS for Hypoxia signaling pathway (HIF-1) antagonists against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347354UWB1.289-WTBRCA1 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347402qHTS for inhibitors of Rabies Virus screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347359HEK293 24hr Apoptosis Induction qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347389qHTS assay for small molecule disruptors of mitochondrial membrane potential screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347371J3T Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347380qHTS for Antimalaria activity screened against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347362Diaphorse counterscreen qHTS: Assay Interference Panel against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347368G06 Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347351U-118MG Cancer Cell Toxicity qHTS against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1347381Inflammasome Signaling qHTS Counterscreen: IL-1-beta AlphaLISA counterscreen against the NCATS CANVASS Library2018ACS central science, Dec-26, Volume: 4, Issue:12
Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.
AID1830027AUCinfinity in Sprague-Dawley rat at 1.25 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1872031Binding affinity to MOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1775334Drug uptake in Sprague-Dawley rat plasma at 1.23 mg/kg, po administered as OPMS liquid formulation measured within 1 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830051Displacement of [125I](+/-)DOI from human recombinant 5-HT2B receptor expressed in CHO cells at 100 nM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830039Displacement of [3H]LSD from human recombinant 5-HT2C receptor expressed in HEK cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830037Antinociceptive activity against ip dosed Sprague-Dawley rats assessed as loser lip retraction measured for 15 mins2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775278Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured in autosampler for 24 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775341Stability of the compound in rat plasma assessed as drug recovery2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775280Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured under freeze-thaw conditions for 3 cycles by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830026Apparent volume of distributed in Sprague-Dawley rat at 1.25 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830047Displacement of [3H]BRL43694 from human recombinant 5-HT3 receptor expressed in CHO cells at 100 nM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1872151Inhibition of KOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1830033Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in cells at 100 nM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830061Antinociceptive activity against Sprague-Dawley rats assessed as lower lip retraction at 17.8 mg/kg, ip measured for 15 mins2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830044Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in HEK cells measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830050Displacement of [125I](+/-)DOI from human recombinant 5-HT2B receptor expressed in CHO cells at 10 uM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1872149Inhibition of MOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1775342Stability of the compound in water-methanol mixture (1:1) assessed as drug recovery2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830045Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in CHO cells measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830042Displacement of [3H]5-CT from human recombinant 5-HT7A receptor expressed in HEK cells by radioligand completion assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1749821Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis
AID1775326Cmax in Sprague-Dawley rat plasma at 0.79 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775275Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured on the bench-top for 2 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775327Tmax in Sprague-Dawley rat plasma at 1.23 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775283Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured at -80 degC for 4 weeks by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830041Displacement of [3H]LSD from human recombinant 5-HT2A receptor expressed in HEK cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830060Antinociceptive activity iv dosed Sprague-Dawley rats assessed as hotplate latency for 60 by hot plate test in presence of WAY1006352021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775279Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured in autosampler for 24 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830056Antinociceptive activity iv dosed Sprague-Dawley rats assessed as hotplate latency for 60 by hot plate test2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830038Displacement of [3H]LSD from human recombinant 5-HT2B receptor expressed in CHO cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830028Clearence in Sprague-Dawley rat at 1.25 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1872033Binding affinity to KOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1830040Displacement of [3H]LSD from human recombinant 5-HT2B receptor expressed in HEK cells by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830032Displacement of [125I]CYP from rat cerebral cortex 5-HT1B receptor at 10 uM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775333Drug uptake in Sprague-Dawley rat plasma at at 0.79 mg/kg, po administered as LKT formulation measured within 1 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830049Displacement of [125I](+/-)DOI from human recombinant 5-HT2C receptor expressed in CHO cells at 100 nM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830052Displacement of [125I](+/-)DOI from human recombinant 5-HT2A receptor expressed in HEK293 cells at 10 uM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830034Displacement of [3H]8-OH-DAPT from human recombinant 5-HT1A receptor expressed in cells at 10 uM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830053Displacement of [125I](+/-)DOI from human recombinant 5-HT2A receptor expressed in HEK293 cells at 100 nM measured after 60 to 90 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830046Displacement of [3H]BRL43694 from human recombinant 5-HT3 receptor expressed in CHO cells at 10 uM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1872032Binding affinity to DOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1775328Cmax in Sprague-Dawley rat plasma at 1.23 mg/kg, po administered as OPMS liquid formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1830035Displacement of [125I]CYP from rat cerebral cortex 5-HT1B receptor at 100 nM measured after 120 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1830048Displacement of [125I](+/-)DOI from human recombinant 5-HT2C receptor expressed in CHO cells at 10 uM measured after 60 mins by radioligand completion assay relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775325Tmax in Sprague-Dawley rat plasma at 0.79 mg/kg, po administered as LKT formulation measured for 24 hrs by UPLC-MS/MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775282Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 2.5 ng/ml measured at -80 degC for 4 weeks by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1775277Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured on the bench-top for 2 hrs by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
AID1872150Inhibition of DOP (unknown origin)2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.
AID1830025Elimination rate constant in Sprague-Dawley rat at 1.25 mg/kg, iv2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Activity of
AID1775281Stability of the compound in rat plasma assessed as proportion of compound deviation from nominal concentration at 160 ng/ml measured under freeze-thaw conditions for 3 cycles by UPLC-MS analysis2021Journal of natural products, 04-23, Volume: 84, Issue:4
Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (200)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.00)18.7374
1990's6 (3.00)18.2507
2000's19 (9.50)29.6817
2010's105 (52.50)24.3611
2020's68 (34.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.10 (24.57)
Research Supply Index5.35 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index115.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews24 (11.43%)6.00%
Reviews0 (0.00%)6.00%
Case Studies14 (6.67%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other172 (81.90%)84.16%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.6920amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
gallic acid
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.		2.1710trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
3,4-dihydroxyphenylacetic acid
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.		2.4110catechols;
dihydroxyphenylacetic acid		human metabolite
histamine
[no description available]		1.9910aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
indoleacetic acid
indoleacetic acid: RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4841. auxin : Any of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").. indole-3-acetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group.		2.1710indole-3-acetic acids;
monocarboxylic acid		auxin;
human metabolite;
mouse metabolite;
plant hormone;
plant metabolite
melatonin
[no description available]		2.1710acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin
N-acetylserotonin : An N-acylserotonin resulting from the formal condensation of the primary amino group of serotonin with the carboxy group of acetic acid.		2.1710acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
naringenin
[no description available]		2.17104'-hydroxyflavanones;
trihydroxyflavanone
phenethylamine
phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016. 2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.		2.1710alkaloid;
aralkylamine;
phenylethylamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
tryptamine
[no description available]		2.1710aminoalkylindole;
aralkylamino compound;
indole alkaloid;
tryptamines		human metabolite;
mouse metabolite;
plant metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		3.4110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
8-hydroxy-2-(di-n-propylamino)tetralin
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively		2.3110phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
[no description available]		2.1710catechin
2,4-dichlorophenoxyacetic acid
2,4-Dichlorophenoxyacetic Acid: An herbicide with irritant effects on the eye and the gastrointestinal system.. 2,4-D : A chlorophenoxyacetic acid that is phenoxyacetic acid in which the ring hydrogens at postions 2 and 4 are substituted by chlorines.		2.0810chlorophenoxyacetic acid;
dichlorobenzene		agrochemical;
defoliant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
environmental contaminant;
phenoxy herbicide;
synthetic auxin
homovanillic acid
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.		2.4110guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
phenytoin
[no description available]		2.0510imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		2.1710indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
5-methoxytryptamine
5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.		2.1710aromatic ether;
primary amino compound;
tryptamines		5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist
7,8-dihydroxyflavone
7,8-dihydroxyflavone : A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's.		2.1710dihydroxyflavoneantidepressant;
antineoplastic agent;
antioxidant;
plant metabolite;
tropomyosin-related kinase B receptor agonist
4',7-dihydroxyflavanone
[no description available]		2.17104'-hydroxyflavanones;
dihydroxyflavanone;
polyphenol		Brassica napus metabolite;
fungal xenobiotic metabolite
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		2.0610acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
am 251
AM 251: an analog of SR141716A; structure given in first source. AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.		2.0710amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles		antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.0110aromatic ether;
nitrile;
polyether;
tertiary amino compound
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		2.17102-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		1.9910clonidine;
imidazoline
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.1101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
fentanyl
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.		3.240anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		2.1710gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
harmaline
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.		2.1710harmala alkaloidoneirogen
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.610aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
kinetin
Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects.. cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.. kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group.		2.08106-aminopurines;
furans		cytokinin;
geroprotector
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		2.1710monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		3.4110benzenes;
diarylmethane;
ketone;
tertiary amino compound
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		2.5520imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		1.9910benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
octopamine
Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.		2.1710phenylethanolamines;
tyramines		neurotransmitter
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		2.0210inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		2.2510aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		2.0610phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
psilocin
psilocin: psilocybine minus the phosphate ester; RN given refers to parent cpd; structure. psilocin : A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional hydroxy substituent at position 4. A hallucinogenic alkaloid isolated in trace amounts from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms").		2.0810hydroxyindoles;
phenols;
tertiary amino compound;
tryptamine alkaloid		drug metabolite;
fungal metabolite;
hallucinogen;
human xenobiotic metabolite;
serotonergic agonist
sb 206553
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source		2.3110pyrroloindole
tyramine
[no description available]		2.4720monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
n-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-n-(2-pyridinyl)cyclohexanecarboxamide
[no description available]		2.3110piperazines
wb 4101
N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine bearing a [(2',6'-dimethoxyphenoxy)ethylamino]methyl group at position 2. An alpha1A-adrenergic selective antagonist.		2.2510aromatic ether;
benzodioxine;
secondary amino compound		alpha-adrenergic antagonist
corticosterone
[no description available]		2.061011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		2.06102-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		2.3110organic heterobicyclic compound;
organonitrogen heterocyclic compound
n-methyltryptamine
N-methyltryptamine: RN given refers to parent cpd		2.1710tryptamine alkaloid;
tryptamines		metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.1510L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.0810erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		3.1510benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
1-naphthaleneacetic acid
1-naphthaleneacetic acid: a plant growth regulator; RN given refers to parent cpd. naphthylacetic acid : A monocarboxylic acid that is naphthalene substituted by a carboxymethyl group at any position.. 1-naphthaleneacetic acid : A naphthylacetic acid substituted by a carboxymethyl group at position 1.		2.0810naphthylacetic acidsynthetic auxin
gramine
gramine : An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3.		2.1710aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
propylhexedrine
propylhexedrine: was heading 1976-94 (see under PROPYLAMINES 1976-90); use PROPYLAMINES to search PROPYLHEXEDRINE 1976-94; alpha-adrenergic stimulant used extensively in nasal decongestant inhalers		7.0610secondary amino compound
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		3.4110mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		3.1140methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
diphenhydramine hydrochloride
Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.		3.4820hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
1,3-dimethoxybenzene
1,3-dimethoxybenzene: structure given in first source		2.0110methoxybenzenes
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		2.1510indazole
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.0710cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
methyl-4-tyramine
methyl-4-tyramine: found in barley malt; RN given refers to parent cpd; structure given in first source		2.1710tyraminesmouse metabolite
nuciferine
nuciferine: CNS depressant; glutamic acid antagonist; RN given refers to (R)-isomer; structure		2.2510
psilocybin
Psilocybin: The major of two hallucinogenic components of Teonanacatl, the sacred mushroom of Mexico, the other component being psilocin. (From Merck Index, 11th ed). psilocybin : A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms").		2.0810organic phosphate;
tertiary amino compound;
tryptamine alkaloid		fungal metabolite;
hallucinogen;
prodrug;
serotonergic agonist
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		2.8930amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
n-methylphenethylamine
N-methylphenethylamine: substrate for type A & B monoamine oxidase; RN given refers to parent cpd		2.1710
4-amino-3-phenylbutyric acid
4-amino-3-phenylbutyric acid: phenyl deriv of GABA; RN given refers to cpd without isomeric designation; structure		2.610organonitrogen compound;
organooxygen compound
tabersonine
[no description available]		2.1710alkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound		antineoplastic agent;
metabolite
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0710benzenes;
phenyl acetates
tramadol
Tramadol: A narcotic analgesic proposed for severe pain. It may be habituating.. tramadol : A racemate consisting of equal amounts of (R,R)- and (S,S)-tramadol. A centrally acting synthetic opioid analgesic, used (as the hydrochloride salt) to treat moderately severe pain. The (R,R)-enantiomer exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer. Originally developed by Gruenenthal GmbH and launched in 1977, it was subsequently isolated from the root bark of the South African tree Nauclea latifolia.. (R,R)-tramadol : A 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol in which both stereocentres have R-configuration; the (R,R)-enantiomer of the racemic opioid analgesic tramadol, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer.		2.77302-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
ipsapirone
[no description available]		2.3110N-arylpiperazine
carfentanil
carfentanil : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of methyl 4-anilino-1-(2-phenylethyl)piperidine-4-carboxylate with propanoic acid.		2.2510methyl ester;
piperidines;
tertiary amino compound;
tertiary carboxamide		mu-opioid receptor agonist;
opioid analgesic;
tranquilizing drug
cathinone
cathinone: alkaloid from khat shrub, Catha edulis; RN given refers to parent cpd without isomeric designation. cathinone : The S stereoisomer of 2-aminopropiophenone.		3.21102-aminopropiophenone;
monoamine alkaloid		central nervous system stimulant;
psychotropic drug
benzylaminopurine
benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group.		2.08106-aminopurinescytokinin;
plant metabolite
betulinic acid
[no description available]		2.5320hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose
pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.		2.1710gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		2.1710dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
loganin
[no description available]		2.0810beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol		anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.02103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
mitraphylline
mitraphylline: isolated from Uncaria tomentosa		7.8330indolizines
glucuronic acid
Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.		2.2110D-glucuronic acidalgal metabolite
quindoline
quindoline: a fused indole-quinoline alkaloid from CRYPTOLEPIS sanguinolenta; structure		2.1710
enkephalin, d-penicillamine (2,5)-
Enkephalin, D-Penicillamine (2,5)-: A disulfide opioid pentapeptide that selectively binds to the DELTA OPIOID RECEPTOR. It possesses antinociceptive activity.. DPDPE : A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.		2.5820heterodetic cyclic peptidedelta-opioid receptor agonist
u 69593
U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.		2.2510monocarboxylic acid amide;
N-alkylpyrrolidine;
organic heterobicyclic compound;
oxaspiro compound		anti-inflammatory agent;
diuretic;
kappa-opioid receptor agonist
tryptoline
tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure		2.1710beta-carbolines
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.0110
pumiliotoxin c
pumiliotoxin C: isolated from skin of Dendrobates pumilio (frog); see also records for pumiliotoxin A, pumiliotoxin B & pumiliotoxins		2.1710
diazaquinomycin a
diazaquinomycin A: structure given in first source		2.1710quinolone
tyrosyl-arginyl-phenylalanyl-lysinamide
tyrosyl-arginyl-phenylalanyl-lysinamide: dermorphin analog		2.4110
fraxinellone
fraxinellone: structure given in first source; RN given for (3R-cis)-isomer		2.17102-benzofurans
glabridin
[no description available]		2.1710hydroxyisoflavansantiplasmodial drug
2',6'-dimethyltyrosine
2',6'-dimethyltyrosine: structure given in first source		2.4110
dermorphin, arg(2)-
dermorphin, Arg(2)-: RN given refers to (L)-isomer		2.4110
salvinorin a
salvinorin A: from the herb, Salvia divinorum		10.9240organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
o-demethyltramadol
O-demethyltramadol: one of the major metabolites of tramadol; structure given in first source; RN given refers to parent compound		2.7730
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene: structure given in first source		2.1710monoterpenoid;
organobromine compound;
organochlorine compound		algal metabolite;
antineoplastic agent;
marine metabolite
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer
[no description available]		2.3110
pseudonicotine
pseudonicotine: structure. (R)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has R-configuration.		2.17103-(1-methylpyrrolidin-2-yl)pyridine
deferrioxamine e
deferrioxamine E: may act as siderophore in Streptomyces. desferrioxamine E : A cyclic hydroxamic acid siderophore that is produced by several bacterial species and exhibits antitumour activity.		2.1710cyclic desferrioxamine;
cyclic hydroxamic acid;
macrocycle		antineoplastic agent;
bacterial metabolite;
marine metabolite;
siderophore
dihydrocorynantheol
dihydrocorynantheol: alkaloid from Mitragyna species; isomer of corynantheidol;		7.0610
4'-hydroxyflavanone
4'-hydroxyflavanone: structure in first source. 4'-hydroxyflavanones : Any hydroxyflavanone having a hydroxy substituent located at position 4'.		2.17104'-hydroxyflavanones;
monohydroxyflavanone
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		2.0110
sb 203580
[no description available]		2.0610imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
lupeol
[no description available]		2.1710pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
wortmannin
[no description available]		2.0610acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
2-oxindole
2-oxindole: RN given refers to parent cpd; structure. indolin-2-one : An indolinone carrying an oxo group at position 2.		2.110gamma-lactam;
indolinone
crinine
crinine: structure in first source		2.1710alkaloid
strychnine
Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.		2.1710monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
micheliolide
micheliolide: has antineoplastic activity; structure in first source		2.1710sesquiterpene lactone
pancracine
pancracine: structure in first source		2.1710isoquinoline alkaloid fundamental parent;
isoquinoline alkaloid
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.4110cyclodextrin
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		2.0810retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
ferulic acid
ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.		2.1710ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.5820benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
iridoids
Iridoids: A type of MONOTERPENES, derived from geraniol. They have the general form of cyclopentanopyran, but in some cases, one of the rings is broken as in the case of secoiridoid. They are different from the similarly named iridals (TRITERPENES).		2.0810
enkephalin, leucine
Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.		2.0610pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
piperine
piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.		2.1710benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
trichodermamide b
trichodermamide B: from cultures of the marine-derived fungus Trichoderma virens; structure in first source		2.1710
buprenorphine
Buprenorphine: A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.. buprenorphine : A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.		3.9330morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		7.0710one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		2.2110cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
hirsutine, (16e,20beta)-isomer
[no description available]		3.0440alkaloidmetabolite
helvolic acid
helvolic acid: structure. helvolic acid : A steroid C-21 acid having a 29-nordammarane skeleton substituted with an acetoxy group at C-16 and oxo groups at C-3 and -7, with double bonds at C-1, -17(20) and -24.		2.17103-oxo-Delta(1) steroid;
acetate ester;
monocarboxylic acid;
steroid acid		antibacterial agent;
fungal metabolite;
mycotoxin
u-50488
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine		2.2510dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist
sch 23390
SCH 23390: a selective D1-receptor antagonist. SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.		2.610benzazepine
paynantheine
paynantheine: structure in first source		8.4660
hirsutine
[no description available]		2.3110
naloxazine
naloxazine: RN given refers to (5alpha)-isomer; structure given in first source		2.2110
chimonanthine
chimonanthine: structure in first source. chimonanthine : A ring assembly that is 2,2',3,3',8,8',8a,8a'-octahydro-1H,1'H-3a,3a'-bipyrrolo[2,3-b]indole substituted by methyl groups at positions 1 and 1'.		2.1710chimonanthine
jhw 015
[no description available]		2.0810indolecarboxamide
3-deoxyisoochracinic acid
3-deoxyisoochracinic acid: structure in first source		2.1710
bilirubin
[no description available]		2.0610biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0610prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.1710beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		2.1710disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.1710harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
baicalein
[no description available]		2.1710trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
fisetin
[no description available]		2.17103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
wogonin
wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.		2.1710dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.2110homodetic cyclic peptide
codeine
[no description available]		3.4820morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
nalorphine
Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.		1.9410morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		8.76100morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		7.6120organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		6.25240morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
endomorphin 1
endomorphin 1: isolated from bovine brain		2.4110oligopeptide
endomorphin 2
endomorphin 2: isolated from bovine brain		2.6120
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		2.1710cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
kaempferol 3-o-rhamnoside
kaempferol 3-O-rhamnoside: from apple (Malus domestica) leaves; structure in first source. afzelin : A glycosyloxyflavone that is kaempferol attached to an alpha-L-rhamnosyl residue at position 3 via a glycosidic linkage.		2.1710glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		anti-inflammatory agent;
antibacterial agent;
plant metabolite
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one: isolated from the Chinese herb Scutellariae radix. oroxylin A : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6.		2.1710dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		4.4760cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		2.31106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
radicinin
radicinin: mold metabolite from plant pathogen Stemphylium radicinum; RN given refers to (2S-(2alpha,3beta,7E))-isomer; structure		2.1710aromatic ketone
calycanthine
calycanthine: the principal alkaloid of the plant family Calycanthaceae; RN given refers to (4bS)-(4balpha,5alpha,10balpha,11alpha)-isomer. calycanthine : The principal alkaloid of the plant family Calycanthaceae.		2.1710aminal;
calycanthaceous alkaloid;
organonitrogen heterocyclic compound
heroin
Heroin: A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed). heroin : A morphinane alkaloid that is morphine bearing two acetyl substituents on the O-3 and O-6 positions. As with other opioids, heroin is used as both an analgesic and a recreational drug. Frequent and regular administration is associated with tolerance and physical dependence, which may develop into addiction. Its use includes treatment for acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain, including end-stage cancer and other terminal illnesses.		7.9630morphinane alkaloidmu-opioid receptor agonist;
opioid analgesic;
prodrug
enkephalin, ala(2)-mephe(4)-gly(5)-
[no description available]		2.930peptide
norbinaltorphimine
norbinaltorphimine: kappa opiate receptor antagonist; structure given in first source		2.7430isoquinolines
xanthoepocin
Xanthoepocin: an antibiotic from Penicillium simplicissimum IFO5762; structure in first source		2.1710
dermorphin
dermorphin: opiate-like peptide present in amphibian skin		2.4110oligopeptide
naltrindole
naltrindole: delta opioid receptor antagonist		2.9840isoquinolines
raubasine
raubasine: RN given refers to (19alpha)-isomer; structure		2.3110yohimban alkaloid
dizocilpine maleate
Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.		2.610maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
herboxidiene
herboxidiene: structure in first source; isolated from Streptomyces chromofuscus; a potent and selective herbicide (e.g. inactive against wheat); up-regulates the gene expression of LDL receptor		2.1710
trk 820
TRK 820: structure in first source		3.3110phenanthrenes
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one
[no description available]		2.1710germacranolide
panduratin a
panduratin A: isolated from Kaempferia pandurata; structure in first source		2.1710diarylheptanoidmetabolite
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
[no description available]		2.1710oligopeptide
13-epi-sclareol
13-epi-sclareol: an unusual labdane diterpene from the roots of Coleus forskohlii with cell growth inhibitory action in breast and uterine cancers in vitro; structure in first source		2.1710
naloxonazine
naloxonazine: binds irreversibly to opiate receptor sites; structure given in first source		2.7130
4-iodo-2,5-dimethoxyphenylisopropylamine, (r)-isomer
[no description available]		2.3110
corynoxine b
corynoxine B: structure in first source		2.3110indolizinesmetabolite
akuammicine
akuammicine: from Strychnos sp;; structure in first source. akuammicine : A monoterpenoid indole alkaloid with formula C20H22N2O2, isolated from several plant species including Alstonia spatulata, Catharanthus roseus and Vinca major.		2.1710methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		plant metabolite
hermitamide b
hermitamide B: isolated from Lyngbya majuscula; structure in first source		2.1710
trans-delta-tocotrienoloic acid
tocotrienoloic acid: from leaves of Tovomitopsis psychotriifolia; structure given in first source		2.1710tocotrienol
corynoxine
corynoxine: structure in first source		2.3110indolizinesmetabolite
nodulisporic acid a
nodulisporic acid A: a novel indole diterpene insecticide; structure in first source		2.1710
9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester
9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester: structure in first source		3.3110
scopadulcic acid b
scopadulcic acid B: isolated from Scorparia dulcis		2.1710
gliocladin c
gliocladin C: structure in first source		2.1710
zincophorin
zincophorin: 25 carbon polypropionate from Streptomyces griseus; griseochelin and M 144255 are the same monocarboxylic acid ionophore		2.1710pyransbacterial metabolite;
ionophore
streptazolin
streptazolin: from culture of Streptomyces sp.; structure in first source		2.1710
chatancin
chatancin: structure in first source		2.1710
scopolamine hydrobromide
[no description available]		2.0510
morelloflavone
morelloflavone: also inhibits cruzain; RN given for (2S-trans)-isomer; structure in first source. (+)-morelloflavone : A biflavonoid found in Rheedia edulis and Garcinia livingstonei.		2.1710biflavonoid;
hydroxyflavanone;
hydroxyflavone		plant metabolite
cinnamosmolide
cinnamosmolide: isolated from several species of Canellaceae family; structure in first source		2.1710
15-deoxygoyazensolide
15-deoxygoyazensolide: an NSAID with schistossomicidal and trypanosomicidal activities; structure in first source		2.1710
mitragynine, (3beta,16e,20beta)-isomer
[no description available]		3.2340
spongia-13(16),14-dien-19-oic acid
spongia-13(16),14-dien-19-oic acid : A tetracyclic diterpenoid that is 3b,4,5,5a,6,7,8,9,9a,9b,10,11-dodecahydrophenanthro[1,2-c]furan substituted by methyl groups at positions 3b, 6 and 9 and a carboxy group at position 6. Isolated from Spongia, it exhibits inhibitory activity against androgen receptor.		2.1710cyclic ether;
monocarboxylic acid;
tetracyclic diterpenoid		androgen antagonist;
metabolite
roquefortine
[no description available]		2.1710pyrroloindole
3-(3,4-dihydroxyphenyl)lactate
3-(3,4-dihydroxyphenyl)lactate : A hydroxy monocarboxylic acid anion that is the conjugate base of 3-(3,4-dihydroxyphenyl)lactic acid; major species at pH 7.3.		2.1710hydroxy monocarboxylic acid anion
cym51010
CYM51010: structure in first source		3.3110
methyl jasmonate
[no description available]		7.0710
marinopyrrole a
marinopyrrole A: antibiotic from a marine Streptomyces sp.; structure in first source. (-)-marinopyrrole A : A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities.		2.1710aromatic ketone;
organochlorine compound;
phenols;
pyrroles		antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite
colletoic acid
colletoic acid: an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor from Colletotrichum gloeosporioides; structure in first source		2.1710
quetiapine fumarate
Quetiapine Fumarate: A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.		2.2110fumarate salt
ipomoeassin f
ipomoeassin F: a cytotoxic macrocyclic glycoresin from the leaves of Ipomoea squamosa from the Suriname rainforest		2.1710
piperidines
Piperidines: A family of hexahydropyridines.		2.0710
6,8-dihydroxy-2,2,4,4-tetramethyl-7-(3-methylbutanoyl)-9-(2-methylpropyl)-9h-xanthene-1,3-dione
[no description available]		2.1710xanthenes
7-hydroxymitragynine
7-hydroxymitragynine: an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa; structure in first source		7.53380alkaloid
mitragynine pseudoindoxyl
mitragynine pseudoindoxyl: derived from Thai medicinal plant MITRAGYNA speciosa; opioid agonist		9.7650
dorrigocin b
dorrigocin B: isolated from the fermentation broth & mycelium of Streptomyces platensis; structure given in first source		2.1710
dorrigocin a
dorrigocin A: isolated from the fermentation broth & mycelium of Streptomyces platensis; structure given in first source		2.1710
cj 15,208
[no description available]		2.4110
2-[5-[(3,4-dichlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine
[no description available]		3.3110triazoles
methylone
[no description available]		2.0810benzodioxoles
tatanan a
tatanan A: from the rhizomes of Acorus tatarinowii Schott; structure in first source		2.1710
ilicicolin h
ilicicolin H: structure in first source. ilicicolin H : An aromatic ketone in which the ketone carbonyl group is attached to a (1R,2R,4aS,7S,8aR)-4,7-dimethyl-1-[(1E)-prop-1-en-1-yl]-1,2,4a,5,6,7,8,8a-octahydronaphthalen-2-yl group and a 4-hydroxy-5-(4-hydroxyphenyl)-2-oxo-1,2-dihydropyridin-3-yl group. Isolated from the from the "imperfect" fungus Cylindrocladium iliciola strain MFC-870.		2.1710aromatic ketone;
carbobicyclic compound;
ilicicolin;
monohydroxypyridine;
octahydronaphthalenes;
phenols;
pyridone		antimicrobial agent;
mitochondrial respiratory-chain inhibitor
tatanan b
tatanan B: from the rhizomes of Acorus tatarinowii Schott; structure in first source		2.1710
3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol
3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol: structure in first source		3.3110
gracilioether f
gracilioether F: structure in first source		2.1710
cryptocaryol a
cryptocaryol A: from Cryptocarya spp.; structure in first source. cryptocaryol A : A member of the class of 2-pyranones that is 5,6-dihydro-2H-pyran-2-one substituted by a 2,4,6,8,10-pentahydroxypentacosyl group at position 6. It has been isolated from Cryptocarya species.		2.17102-pyranones;
pentol		plant metabolite
22-thiocyanatosalvinorin a
22-thiocyanatosalvinorin A: structure in first source		3.7820
n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide: a street drug; structure in first source		2.1510
tetrahydroamentoflavone
tetrahydroamentoflavone: isolated from Semecarpus anacardium; structure in first source		2.1710
nataxazole
nataxazole: has antineoplastic activity; isolated from Streptomyces; structure in first source		2.1710
preproenkephalin
preproenkephalin: initial enkephalin precursor		2.0610
gallic acid
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.		2.1710trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
indoleacetic acid
indoleacetic acid: RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4841. auxin : Any of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").. indole-3-acetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group.		2.1710indole-3-acetic acids;
monocarboxylic acid		auxin;
human metabolite;
mouse metabolite;
plant hormone;
plant metabolite
melatonin
[no description available]		2.1710acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin
N-acetylserotonin : An N-acylserotonin resulting from the formal condensation of the primary amino group of serotonin with the carboxy group of acetic acid.		2.1710acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
naringenin
[no description available]		2.17104'-hydroxyflavanones;
trihydroxyflavanone
phenethylamine
phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016. 2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.		2.1710alkaloid;
aralkylamine;
phenylethylamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
tryptamine
[no description available]		2.1710aminoalkylindole;
aralkylamino compound;
indole alkaloid;
tryptamines		human metabolite;
mouse metabolite;
plant metabolite
8-hydroxy-2-(di-n-propylamino)tetralin
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively		2.3110phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
[no description available]		2.1710catechin
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		2.1710indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
5-methoxytryptamine
5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.. 5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.		2.1710aromatic ether;
primary amino compound;
tryptamines		5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist
7,8-dihydroxyflavone
7,8-dihydroxyflavone : A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's.		2.1710dihydroxyflavoneantidepressant;
antineoplastic agent;
antioxidant;
plant metabolite;
tropomyosin-related kinase B receptor agonist
4',7-dihydroxyflavanone
[no description available]		2.17104'-hydroxyflavanones;
dihydroxyflavanone;
polyphenol		Brassica napus metabolite;
fungal xenobiotic metabolite
harmaline
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.		2.1710harmala alkaloidoneirogen
octopamine
Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.		2.1710phenylethanolamines;
tyramines		neurotransmitter
sb 206553
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source		2.3110pyrroloindole
tyramine
[no description available]		2.1710monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
n-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-n-(2-pyridinyl)cyclohexanecarboxamide
[no description available]		2.3110piperazines
n-methyltryptamine
N-methyltryptamine: RN given refers to parent cpd		2.1710tryptamine alkaloid;
tryptamines		metabolite
gramine
gramine : An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3.		2.1710aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.1710methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
methyl-4-tyramine
methyl-4-tyramine: found in barley malt; RN given refers to parent cpd; structure given in first source		2.1710tyraminesmouse metabolite
n-methylphenethylamine
N-methylphenethylamine: substrate for type A & B monoamine oxidase; RN given refers to parent cpd		2.1710
tabersonine
[no description available]		2.1710alkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound		antineoplastic agent;
metabolite
ipsapirone
[no description available]		2.3110N-arylpiperazine
betulinic acid
[no description available]		2.1710hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose
pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.		2.1710gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		2.1710dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
mitraphylline
mitraphylline: isolated from Uncaria tomentosa		2.3110indolizines
quindoline
quindoline: a fused indole-quinoline alkaloid from CRYPTOLEPIS sanguinolenta; structure		2.1710
tryptoline
tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure		2.1710beta-carbolines
pumiliotoxin c
pumiliotoxin C: isolated from skin of Dendrobates pumilio (frog); see also records for pumiliotoxin A, pumiliotoxin B & pumiliotoxins		2.1710
diazaquinomycin a
diazaquinomycin A: structure given in first source		2.1710quinolone
tyrosyl-arginyl-phenylalanyl-lysinamide
tyrosyl-arginyl-phenylalanyl-lysinamide: dermorphin analog		2.4110
fraxinellone
fraxinellone: structure given in first source; RN given for (3R-cis)-isomer		2.17102-benzofurans
glabridin
[no description available]		2.1710hydroxyisoflavansantiplasmodial drug
2',6'-dimethyltyrosine
2',6'-dimethyltyrosine: structure given in first source		2.4110
dermorphin, arg(2)-
dermorphin, Arg(2)-: RN given refers to (L)-isomer		2.4110
salvinorin a
salvinorin A: from the herb, Salvia divinorum		2.4110organic heterotricyclic compound;
organooxygen compound		metabolite;
oneirogen
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene: structure given in first source		2.1710monoterpenoid;
organobromine compound;
organochlorine compound		algal metabolite;
antineoplastic agent;
marine metabolite
pseudonicotine
pseudonicotine: structure. (R)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has R-configuration.		2.17103-(1-methylpyrrolidin-2-yl)pyridine
deferrioxamine e
deferrioxamine E: may act as siderophore in Streptomyces. desferrioxamine E : A cyclic hydroxamic acid siderophore that is produced by several bacterial species and exhibits antitumour activity.		2.1710cyclic desferrioxamine;
cyclic hydroxamic acid;
macrocycle		antineoplastic agent;
bacterial metabolite;
marine metabolite;
siderophore
4'-hydroxyflavanone
4'-hydroxyflavanone: structure in first source. 4'-hydroxyflavanones : Any hydroxyflavanone having a hydroxy substituent located at position 4'.		2.17104'-hydroxyflavanones;
monohydroxyflavanone
lupeol
[no description available]		2.1710pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
crinine
crinine: structure in first source		2.1710alkaloid
strychnine
Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.		2.1710monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
micheliolide
micheliolide: has antineoplastic activity; structure in first source		2.1710sesquiterpene lactone
pancracine
pancracine: structure in first source		2.1710isoquinoline alkaloid fundamental parent;
isoquinoline alkaloid
ferulic acid
ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.		2.1710ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
piperine
piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.		2.1710benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
trichodermamide b
trichodermamide B: from cultures of the marine-derived fungus Trichoderma virens; structure in first source		2.1710
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		7.0710one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
hirsutine, (16e,20beta)-isomer
[no description available]		2.7220alkaloidmetabolite
helvolic acid
helvolic acid: structure. helvolic acid : A steroid C-21 acid having a 29-nordammarane skeleton substituted with an acetoxy group at C-16 and oxo groups at C-3 and -7, with double bonds at C-1, -17(20) and -24.		2.17103-oxo-Delta(1) steroid;
acetate ester;
monocarboxylic acid;
steroid acid		antibacterial agent;
fungal metabolite;
mycotoxin
paynantheine
paynantheine: structure in first source		8.4660
hirsutine
[no description available]		2.3110
chimonanthine
chimonanthine: structure in first source. chimonanthine : A ring assembly that is 2,2',3,3',8,8',8a,8a'-octahydro-1H,1'H-3a,3a'-bipyrrolo[2,3-b]indole substituted by methyl groups at positions 1 and 1'.		2.1710chimonanthine
3-deoxyisoochracinic acid
3-deoxyisoochracinic acid: structure in first source		2.1710
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.1710beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		2.1710disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.1710harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
baicalein
[no description available]		2.1710trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
fisetin
[no description available]		2.17103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
wogonin
wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.		2.1710dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		2.4110morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
endomorphin 1
endomorphin 1: isolated from bovine brain		2.4110oligopeptide
endomorphin 2
endomorphin 2: isolated from bovine brain		2.4110
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		2.1710cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
kaempferol 3-o-rhamnoside
kaempferol 3-O-rhamnoside: from apple (Malus domestica) leaves; structure in first source. afzelin : A glycosyloxyflavone that is kaempferol attached to an alpha-L-rhamnosyl residue at position 3 via a glycosidic linkage.		2.1710glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		anti-inflammatory agent;
antibacterial agent;
plant metabolite
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one: isolated from the Chinese herb Scutellariae radix. oroxylin A : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6.		2.1710dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
radicinin
radicinin: mold metabolite from plant pathogen Stemphylium radicinum; RN given refers to (2S-(2alpha,3beta,7E))-isomer; structure		2.1710aromatic ketone
calycanthine
calycanthine: the principal alkaloid of the plant family Calycanthaceae; RN given refers to (4bS)-(4balpha,5alpha,10balpha,11alpha)-isomer. calycanthine : The principal alkaloid of the plant family Calycanthaceae.		2.1710aminal;
calycanthaceous alkaloid;
organonitrogen heterocyclic compound
xanthoepocin
Xanthoepocin: an antibiotic from Penicillium simplicissimum IFO5762; structure in first source		2.1710
dermorphin
dermorphin: opiate-like peptide present in amphibian skin		2.4110oligopeptide
raubasine
raubasine: RN given refers to (19alpha)-isomer; structure		2.3110yohimban alkaloid
herboxidiene
herboxidiene: structure in first source; isolated from Streptomyces chromofuscus; a potent and selective herbicide (e.g. inactive against wheat); up-regulates the gene expression of LDL receptor		2.1710
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one
[no description available]		2.1710germacranolide
panduratin a
panduratin A: isolated from Kaempferia pandurata; structure in first source		2.1710diarylheptanoidmetabolite
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
[no description available]		2.1710oligopeptide
13-epi-sclareol
13-epi-sclareol: an unusual labdane diterpene from the roots of Coleus forskohlii with cell growth inhibitory action in breast and uterine cancers in vitro; structure in first source		2.1710
4-iodo-2,5-dimethoxyphenylisopropylamine, (r)-isomer
[no description available]		2.3110
corynoxine b
corynoxine B: structure in first source		2.3110indolizinesmetabolite
akuammicine
akuammicine: from Strychnos sp;; structure in first source. akuammicine : A monoterpenoid indole alkaloid with formula C20H22N2O2, isolated from several plant species including Alstonia spatulata, Catharanthus roseus and Vinca major.		2.1710methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		plant metabolite
hermitamide b
hermitamide B: isolated from Lyngbya majuscula; structure in first source		2.1710
trans-delta-tocotrienoloic acid
tocotrienoloic acid: from leaves of Tovomitopsis psychotriifolia; structure given in first source		2.1710tocotrienol
corynoxine
corynoxine: structure in first source		2.3110indolizinesmetabolite
nodulisporic acid a
nodulisporic acid A: a novel indole diterpene insecticide; structure in first source		2.1710
scopadulcic acid b
scopadulcic acid B: isolated from Scorparia dulcis		2.1710
gliocladin c
gliocladin C: structure in first source		2.1710
zincophorin
zincophorin: 25 carbon polypropionate from Streptomyces griseus; griseochelin and M 144255 are the same monocarboxylic acid ionophore		2.1710pyransbacterial metabolite;
ionophore
streptazolin
streptazolin: from culture of Streptomyces sp.; structure in first source		2.1710
chatancin
chatancin: structure in first source		2.1710
morelloflavone
morelloflavone: also inhibits cruzain; RN given for (2S-trans)-isomer; structure in first source. (+)-morelloflavone : A biflavonoid found in Rheedia edulis and Garcinia livingstonei.		2.1710biflavonoid;
hydroxyflavanone;
hydroxyflavone		plant metabolite
cinnamosmolide
cinnamosmolide: isolated from several species of Canellaceae family; structure in first source		2.1710
15-deoxygoyazensolide
15-deoxygoyazensolide: an NSAID with schistossomicidal and trypanosomicidal activities; structure in first source		2.1710
mitragynine, (3beta,16e,20beta)-isomer
[no description available]		3.0430
spongia-13(16),14-dien-19-oic acid
spongia-13(16),14-dien-19-oic acid : A tetracyclic diterpenoid that is 3b,4,5,5a,6,7,8,9,9a,9b,10,11-dodecahydrophenanthro[1,2-c]furan substituted by methyl groups at positions 3b, 6 and 9 and a carboxy group at position 6. Isolated from Spongia, it exhibits inhibitory activity against androgen receptor.		2.1710cyclic ether;
monocarboxylic acid;
tetracyclic diterpenoid		androgen antagonist;
metabolite
roquefortine
[no description available]		2.1710pyrroloindole
3-(3,4-dihydroxyphenyl)lactate
3-(3,4-dihydroxyphenyl)lactate : A hydroxy monocarboxylic acid anion that is the conjugate base of 3-(3,4-dihydroxyphenyl)lactic acid; major species at pH 7.3.		2.1710hydroxy monocarboxylic acid anion
marinopyrrole a
marinopyrrole A: antibiotic from a marine Streptomyces sp.; structure in first source. (-)-marinopyrrole A : A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities.		2.1710aromatic ketone;
organochlorine compound;
phenols;
pyrroles		antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite
colletoic acid
colletoic acid: an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor from Colletotrichum gloeosporioides; structure in first source		2.1710
ipomoeassin f
ipomoeassin F: a cytotoxic macrocyclic glycoresin from the leaves of Ipomoea squamosa from the Suriname rainforest		2.1710
6,8-dihydroxy-2,2,4,4-tetramethyl-7-(3-methylbutanoyl)-9-(2-methylpropyl)-9h-xanthene-1,3-dione
[no description available]		2.1710xanthenes
7-hydroxymitragynine
7-hydroxymitragynine: an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa; structure in first source		8.5260alkaloid
dorrigocin b
dorrigocin B: isolated from the fermentation broth & mycelium of Streptomyces platensis; structure given in first source		2.1710
dorrigocin a
dorrigocin A: isolated from the fermentation broth & mycelium of Streptomyces platensis; structure given in first source		2.1710
cj 15,208
[no description available]		2.4110
tatanan a
tatanan A: from the rhizomes of Acorus tatarinowii Schott; structure in first source		2.1710
ilicicolin h
ilicicolin H: structure in first source. ilicicolin H : An aromatic ketone in which the ketone carbonyl group is attached to a (1R,2R,4aS,7S,8aR)-4,7-dimethyl-1-[(1E)-prop-1-en-1-yl]-1,2,4a,5,6,7,8,8a-octahydronaphthalen-2-yl group and a 4-hydroxy-5-(4-hydroxyphenyl)-2-oxo-1,2-dihydropyridin-3-yl group. Isolated from the from the "imperfect" fungus Cylindrocladium iliciola strain MFC-870.		2.1710aromatic ketone;
carbobicyclic compound;
ilicicolin;
monohydroxypyridine;
octahydronaphthalenes;
phenols;
pyridone		antimicrobial agent;
mitochondrial respiratory-chain inhibitor
tatanan b
tatanan B: from the rhizomes of Acorus tatarinowii Schott; structure in first source		2.1710
gracilioether f
gracilioether F: structure in first source		2.1710
cryptocaryol a
cryptocaryol A: from Cryptocarya spp.; structure in first source. cryptocaryol A : A member of the class of 2-pyranones that is 5,6-dihydro-2H-pyran-2-one substituted by a 2,4,6,8,10-pentahydroxypentacosyl group at position 6. It has been isolated from Cryptocarya species.		2.17102-pyranones;
pentol		plant metabolite
22-thiocyanatosalvinorin a
22-thiocyanatosalvinorin A: structure in first source		2.4110
tetrahydroamentoflavone
tetrahydroamentoflavone: isolated from Semecarpus anacardium; structure in first source		2.1710
nataxazole
nataxazole: has antineoplastic activity; isolated from Streptomyces; structure in first source		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		03.2660
Chemical Dependence
[description not available]		07.4330
Substance-Related Disorders
Disorders related to substance use or abuse.		07.4330
Ache
[description not available]		05.790
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		05.790
Congenital Zika Syndrome
[description not available]		02.6620
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		04.6690
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.6620
Nociceptive Pain
Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.		02.7220
2019 Novel Coronavirus Disease
[description not available]		02.3110
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		02.3110
Morphine Abuse
[description not available]		02.7620
Addiction, Opioid
[description not available]		06.12130
Drug Withdrawal Symptoms
[description not available]		06.55180
Morphine Dependence
Strong dependence, both physiological and emotional, upon morphine.		02.7620
Opioid-Related Disorders
Disorders related to or resulting from abuse or misuse of OPIOIDS.		06.12130
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		06.55180
Acute Hypercapnic Respiratory Failure
[description not available]		02.4110
Respiratory Insufficiency
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)		02.4110
Delayed Effects, Prenatal Exposure
[description not available]		02.610
Acute Pain
Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.		03.5240
Nerve Pain
[description not available]		02.610
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.610
Benign Neoplasms, Brain
[description not available]		02.610
Glial Cell Tumors
[description not available]		02.610
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.610
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		07.610
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		07.520
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.2110
Cardiac Death
[description not available]		02.2110
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		04.2960
Alcohol Abuse
[description not available]		02.6920
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		02.6920
Hemorrhagic Stroke
Stroke due to rupture of a weakened blood vessel in the brain (e.g., CEREBRAL HEMISPHERES; CEREBELLUM; SUBARACHNOID SPACE).		02.2510
Brain Hemorrhage, Cerebral
[description not available]		02.2510
Cerebral Hemorrhage
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.		02.2510
Acute Liver Injury, Drug-Induced
[description not available]		03.1710
Bile Duct Obstruction
[description not available]		03.1710
Cholestasis
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).		03.1710
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		03.1710
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.1510
Anxiety Neuroses
[description not available]		03.0910
Anxiety Disorders
Persistent and disabling ANXIETY.		03.0910
Complications, Pregnancy
[description not available]		02.1710
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.1710
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0810
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		02.4820
Cancer of Colon
[description not available]		02.110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.110
Cardiac Toxicity
[description not available]		02.110
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		07.110
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		03.0410
Aspiration, Respiratory
[description not available]		02.1510
Consciousness, Loss of
[description not available]		02.1510
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		02.0510
Neuromuscular Blockade
The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.		07.0510
Coma
A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.		02.0510
Absence Seizure
[description not available]		02.0510
Poisoning
Used with drugs, chemicals, and industrial materials for human or animal poisoning, acute or chronic, whether the poisoning is accidental, occupational, suicidal, by medication error, or by environmental exposure.		02.0510
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.0510
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		07.0610
Adverse Drug Event
[description not available]		02.4720
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		02.4720
Bile Duct Obstruction, Intrahepatic
[description not available]		02.0610
Cholestasis, Intrahepatic
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).		02.0610
Idiopathic Hypoparathyroidism
A condition of low or absent PTH level and HYPOCALCEMIA. It usually occurs as part of an autoimmune syndrome.		02.0610
Hypoparathyroidism
A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.		02.0610
Edema, Pulmonary
[description not available]		02.0810
Pulmonary Edema
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.		02.0810